Home » ETF » CNCR

CNCR - Loncar Cancer Immunotherapy ETF

Stock Price: $29.79 USD 0.73 (2.49%)
Updated Apr 21, 2021 4:00 PM EDT - Market closed
Assets $42.17M
NAV $29.08
Expense Ratio 0.79%
PE Ratio n/a
Beta (5Y) 1.22
Dividend (ttm) $0.29
Dividend Yield 0.99%
Ex-Dividend Date Dec 30, 2020
1-Year Return -
Trading Day April 21
Last Price $29.79
Previous Close $29.07
Change ($) 0.73
Change (%) 2.49%
Day's Open 29.16
Day's Range 28.85 - 29.79
Day's Volume 4,282
52-Week Range 21.54 - 35.82

Fund Description

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.

Asset Class
Equity
Sector
Biotech
Region
Global
Inception Date
Oct 13, 2015
Exchange
NASDAQ
Ticker Symbol
CNCR
Index Tracked
Loncar Cancer Immunotherapy Index

Top 10 Holdings

45.42% of assets
NameSymbolWeight
I-MabIMAB5.74%
MacroGenicsMGNX5.55%
BeiGeneBGNE4.81%
BioNTech SEBNTX4.50%
Allogene TherapeuticsALLO4.45%
Nektar TherapeuticsNKTR4.19%
Bristol-Myers SquibbBMY4.11%
Gilead SciencesGILD4.10%
Arcus BiosciencesRCUS4.04%
Regeneron PharmaceuticalsREGN3.94%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Dec 30, 2020$0.288Jan 4, 2021
Dec 28, 2017$0.3502Jan 2, 2018
Dec 29, 2015$0.106Jan 4, 2016
Full Dividend History

News

Hide News
  • All
  • Videos
  • Conversation

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

Other tickers mentioned: ARKG, BBH, BNTX, BTEC, FBT, IBB, PBE ...
3 months ago - Zacks Investment Research

Both stock index ETFs and biotech stocks and ETFs have been on a tear lately thanks to promising coronavirus vaccine developments from several major pharmaceutical companies. But this week, the U.K. bec...

Other tickers mentioned: IBB, XBI
4 months ago - ETF Trends

Healthcare stocks and ETFs are continuing to outperform as investors are optimistic about an upcoming vaccine for the coronavirus, which has been a blight on the globe since early this year. There has b...

Other tickers mentioned: BBH, IBB
4 months ago - ETF Trends

Monday saw stocks and index ETFs surge, after the announcement from Pfizer that the pharmaceutical giant had a vaccine candidate with an over 90% effectiveness in clinical trials. Now another biotech, M...

Other tickers mentioned: BBH, IBB
5 months ago - ETF Trends

Last week was extremely volatile for Wall Street with the S&P 500, the Dow Jones and the Nasdaq losing about 2.5%, 1.7% and 4.1%, respectively.

Other tickers mentioned: DWSH, EPHE, GRU, ITB, PGM, WIL
7 months ago - Zacks Investment Research

Amid the uncertainties, a few sectors have survived last week's turmoil. We have highlighted six of that could be compelling picks for the weeks ahead as long as volatility persists.

Other tickers mentioned: AZN, GERM, ITB, MXI, RING, TAN
7 months ago - Zacks Investment Research

We have highlighted ETFs that were at the forefront of the market rebound on Sep 9 and will continue to do so if market sentiments remain positive.

Other tickers mentioned: ARKQ, FNGS, PBW, PTH
7 months ago - Zacks Investment Research

Per the latest data from an early stage clinical trial, Moderna's experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults.

Other tickers mentioned: BBH, BTEC, GERM, IBB, IDNA, XBI
7 months ago - Zacks Investment Research

Stock indexes and ETFs rocketed higher and are continuing the uptrend in trading Wednesday after Moderna said its coronavirus vaccine generated antibodies in elderly patients for the first time, creatin...

Other tickers mentioned: BBH, IBB, XBI
7 months ago - ETF Trends

Biotech ETFs are, in a word, hot.

Other tickers mentioned: BTEC, GERM, IBB, PBE, XBI
8 months ago - Kiplinger

Biotech ETFs are popular and delivering for investors, but not all of these funds need the Covid-19 pandemic to soar.

Other tickers mentioned: ARKG, BTEC, FBT, GERM, SBIO, XBI
8 months ago - InvestorPlace

Moderna plans to begin the Phase 3 study of mRNA-1273 this month.

Other tickers mentioned: MRNA, BBH, BTEC, FBT, GERM, IBB, IDNA ...
9 months ago - Zacks Investment Research

Stock futures rocketed higher and are continuing the uptrend in overnight trading on Tuesday after Moderna said its coronavirus vaccine generated antibodies in all patients in an early trial, creating o...

Other tickers mentioned: BBH, BTEC, IBB, XBI
9 months ago - ETF Trends

The Covid-19 pandemic dinged a slew of asset classes, but these ETFs are positioned to benefit when the virus is squashed.

Other tickers mentioned: ARKF, AWAY, BJK, EWZ, JETS, XLI
10 months ago - InvestorPlace

With the race to find a vaccine for the coronavirus, now drugmaker AstraZeneca is the latest to receive funding to generate a panacea.

Other tickers mentioned: AZN, BBH, IBB, XBI
11 months ago - ETF Trends

Shares of biotechnology company Moderna Inc (NASDAQ: MRNA) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress.

Other tickers mentioned: BTEC, IDNA
11 months ago - Benzinga

U.S. stocks are continuing to soar higher on Monday, moving into positive territory for May, following news that drugmaker Moderna released positive, preliminary results from the first human trial of it...

Other tickers mentioned: IBB, XBI
11 months ago - ETF Trends

The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.

Other tickers mentioned: IBB, PBE, XBI
11 months ago - Zacks Investment Research

Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.

Other tickers mentioned: BBH, FBT, IBB, IDNA, IHE, IHF, PBE ...
11 months ago - Zacks Investment Research

Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.

Other tickers mentioned: ARKG, AYTU, BBH, CNTG, CODX, FTSV, IBB ...
1 year ago - Zacks Investment Research

Can biotech ETFs repeat its success story of 2019 in the election year of 2020?

Other tickers mentioned: BBC, HTEC, IBB, IDNA, PBE, SBIO, XBI
1 year ago - Zacks Investment Research

Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

Other tickers mentioned: BBC, GNOM, IBB, SBIO, XBI
1 year ago - Zacks Investment Research

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.

Other tickers mentioned: ARKG, BBH, BBP, BTEC, FBT, IBB, PBE ...
1 year ago - Zacks Investment Research

Healthcare bounced back with an outperformance starting the fourth quarter.

Other tickers mentioned: BBC, GNOM, IHF, IRWD, JNCE, OSMT, SBIO ...
1 year ago - Zacks Investment Research

Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.

Other tickers mentioned: ARKG, PBE, PTH, XBI
1 year ago - Zacks Investment Research

Biotechnology company Amgen (NasdaqGS: AMGN) is throwing $2.7 billion into BeiGene (NasdaqGS: BGNE), sending the Chinese biotech’s shares surging and bolstering sector-related ETFs. Among the top perfor...

Other tickers mentioned: BBH
1 year ago - ETF Trends